Silence Therapeutics | Evaluate

Lilly signs up Verve to take on Novartis and Amgen

Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.

November 07, 2022

AHA 2022 – Amgen looks good in metabolic disease

With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.

April 04, 2022

ACC 2022 – Silence takes on Novartis and Amgen

July 02, 2021

Smaller companies set for third-quarter catalysts

The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.

March 25, 2020

Astrazeneca throws Silence an $80m lifeline

Silence has received an important validation, but making progress could be tough.

August 06, 2019

Share price movers – July 2019

December 10, 2018

Silence’s delivery falls short of its promise

September 08, 2016

Interview – Immodulon rises from the ashes of SR Pharma

April 16, 2014

Novartis exit caps tough period for RNAi research

April 10, 2013

Silence needs to make a big noise with new cash

September 15, 2011

EP Vantage Interview – Noxxon's transformation entering pivotal phase

Load More